{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:23:29Z","timestamp":1780568609569,"version":"3.54.1"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068634"],"award-info":[{"award-number":["UM1 AI068634"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068636"],"award-info":[{"award-number":["UM1 AI068636"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI106701"],"award-info":[{"award-number":["UM1 AI106701"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007301","name":"Harvard University Center for AIDS Research","doi-asserted-by":"publisher","award":["NIH P30 AI060354"],"award-info":[{"award-number":["NIH P30 AI060354"]}],"id":[{"id":"10.13039\/100007301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011072","name":"University of North Carolina at Chapel Hill Center for AIDS Research","doi-asserted-by":"crossref","award":["NIH P30 AI050410"],"award-info":[{"award-number":["NIH P30 AI050410"]}],"id":[{"id":"10.13039\/100011072","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Biological sex and the estrogen receptor alpha (ESR1) modulate human immunodeficiency virus (HIV) activity. Few women have enrolled in clinical trials of latency reversal agents (LRAs); their effectiveness in women is unknown. We hypothesized that ESR1 antagonism would augment induction of HIV expression by the LRA vorinostat.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>AIDS Clinical Trials Group A5366 enrolled 31 virologically suppressed, postmenopausal women on antiretroviral therapy. Participants were randomized 2:1 to receive tamoxifen (arm A, TAMOX\/VOR) or observation (arm B, VOR) for 5 weeks followed by 2 doses of vorinostat. Primary end points were safety and the difference between arms in HIV RNA induction after vorinostat. Secondary analyses included histone 4 acetylation, HIV DNA, and plasma viremia by single copy assay (SCA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>No significant adverse events were attributed to study treatments. Tamoxifen did not enhance vorinostat-induced HIV transcription (between-arm ratio, 0.8; 95% confidence interval [CI], .2\u20132.4). Vorinostat-induced HIV transcription was higher in participants with increases in H4Ac (fold increase, 2.78; 95% CI, 1.34\u20135.79) vs those 9 who did not (fold increase, 1.04; 95% CI, .25\u20134.29). HIV DNA and SCA plasma viremia did not substantially change.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Tamoxifen did not augment vorinostat-induced HIV RNA expression in postmenopausal women. The modest latency reversal activity of vorinostat, postmenopausal status, and low level of HIV RNA expression near the limits of quantification limited assessment of the impact of tamoxifen. This study is the first HIV cure trial done exclusively in women and establishes both the feasibility and necessity of investigating novel HIV cure strategies in women living with HIV.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT03382834.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciac136","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T20:11:37Z","timestamp":1645128697000},"page":"1389-1396","source":"Crossref","is-referenced-by-count":17,"title":["Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial"],"prefix":"10.1093","volume":"75","author":[{"given":"Eileen P","family":"Scully","sequence":"first","affiliation":[{"name":"Departement of Medicine, Johns Hopkins University , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia","family":"Aga","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Harvard T.H. Chan School of Public Health , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athe","family":"Tsibris","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancie","family":"Archin","sequence":"additional","affiliation":[{"name":"University of North Carolina , Chapel Hill, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Starr","sequence":"additional","affiliation":[{"name":"ACTG Clinical Research Site, Ohio State University , Hilliard, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Ma","sequence":"additional","affiliation":[{"name":"Translational Pharmacology Research Core, University at Buffalo , Buffalo, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene D","family":"Morse","sequence":"additional","affiliation":[{"name":"Translational Pharmacology Research Core, University at Buffalo , Buffalo, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen E","family":"Squires","sequence":"additional","affiliation":[{"name":"Merck Research Labs , Upper Gwynned, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie J","family":"Howell","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease and Vaccines , Merck and Co, West Point, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease and Vaccines , Merck and Co, West Point, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Hosey","sequence":"additional","affiliation":[{"name":"ACTG Network Coordinating Center , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott F","family":"Sieg","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Microbiology, Case Western Reserve University , Cleveland, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynsay","family":"Ehui","sequence":"additional","affiliation":[{"name":"Whitman-Walker Health , Washington, D.C. , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Giguel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendyll","family":"Coxen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Dobrowolski","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Microbiology, Case Western Reserve University , Cleveland, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Deeks","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Chomont","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Infectiology and Immunology, Universite\u0301 de Montre\u0301al, Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CHUM) , Montreal , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Connick","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Arizona , Tucson, Arizona , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Godfrey","sequence":"additional","affiliation":[{"name":"Office of the Global AIDS Coordinator, Department of State , Washington D.C. , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Karn","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Microbiology, Case Western Reserve University , Cleveland, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R","family":"Kuritzkes","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J","family":"Bosch","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Harvard T.H. Chan School of Public Health , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh T","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Harvard University , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"2022101219182812300_CIT0001","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/487439a","article-title":"HIV: shock and kill.","volume":"487","author":"Deeks","year":"2012","journal-title":"Nature"},{"key":"2022101219182812300_CIT0002","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nature11286","article-title":"Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.","volume":"487","author":"Archin","year":"2012","journal-title":"Nature"},{"key":"2022101219182812300_CIT0003","doi-asserted-by":"crossref","first-page":"aaf6517","DOI":"10.1126\/science.aaf6517","article-title":"Latency reversal and viral clearance to cure HIV-1.","volume":"353","author":"Margolis","year":"2016","journal-title":"Science"},{"key":"2022101219182812300_CIT0004","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","article-title":"Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure.","volume":"155","author":"Ho","year":"2013","journal-title":"Cell"},{"key":"2022101219182812300_CIT0005","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/COH.0000000000000484","article-title":"Lessons learned from HIV antiretroviral treatment interruption trials.","volume":"13","author":"Wen","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"2022101219182812300_CIT0006","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.3389\/fmicb.2019.03060","article-title":"Current status of latency reversing agents facing the heterogeneity of HIV-1 cellular and tissue reservoirs.","volume":"10","author":"Ait-Ammar","year":"2019","journal-title":"Front Microbiol"},{"key":"2022101219182812300_CIT0007","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/QAD.0000000000002397","article-title":"Immune checkpoint inhibitors in people living with HIV: what about anti-HIV effects?","volume":"34","author":"Abbar","year":"2020","journal-title":"AIDS"},{"key":"2022101219182812300_CIT0008","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/QAI.0000000000000842","article-title":"A systematic review of the inclusion (or exclusion) of women in HIV research: from clinical studies of antiretrovirals and vaccines to cure strategies.","volume":"71","author":"Curno","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022101219182812300_CIT0009","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/aid.2014.0205","article-title":"Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review.","volume":"31","author":"Johnston","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2022101219182812300_CIT0010","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11904-018-0383-2","article-title":"Sex differences in HIV infection.","volume":"15","author":"Scully","year":"2018","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2022101219182812300_CIT0011","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1086\/341249","article-title":"Does patient sex affect human immunodeficiency virus levels?.","volume":"35","author":"Gandhi","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2022101219182812300_CIT0012","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/infdis\/jit575","article-title":"CCR5 expression is reduced in lymph nodes of HIV type 1-infected women, compared with men, but does not mediate sex-based differences in viral loads.","volume":"209","author":"Meditz","year":"2014","journal-title":"J Infect Dis"},{"key":"2022101219182812300_CIT0013","doi-asserted-by":"crossref","first-page":"e00758\u201320","DOI":"10.1128\/JVI.00758-20","article-title":"Better viral control despite higher CD4(+) T cell activation during acute HIV-1 infection in Zambian women is linked to the sex hormone estradiol.","volume":"94","author":"El-Badry","year":"2020","journal-title":"J Virol"},{"key":"2022101219182812300_CIT0014","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/nm.2004","article-title":"Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1.","volume":"15","author":"Meier","year":"2009","journal-title":"Nat Med"},{"key":"2022101219182812300_CIT0015","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1086\/314967","article-title":"Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters.","volume":"180","author":"Sterling","year":"1999","journal-title":"J Infect Dis"},{"key":"2022101219182812300_CIT0016","doi-asserted-by":"crossref","first-page":"e1006285","DOI":"10.1371\/journal.ppat.1006285","article-title":"Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.","volume":"13","author":"Gandhi","year":"2017","journal-title":"PLoS Pathog"},{"key":"2022101219182812300_CIT0017","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/infdis\/jiy617","article-title":"Sex-based differences in human immunodeficiency virus type 1 reservoir activity and residual immune activation.","volume":"219","author":"Scully","year":"2019","journal-title":"J Infect Dis"},{"key":"2022101219182812300_CIT0018","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/infdis\/jiaa373","article-title":"Male sex and obesity are associated with residual plasma HIV-1 viremia in persons on long-term antiretroviral therapy.","volume":"223","author":"Cyktor","year":"2021","journal-title":"J Infect Dis"},{"key":"2022101219182812300_CIT0019","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1093\/infdis\/jiaa298","article-title":"Impact of biological sex on immune activation and frequency of the latent HIV reservoir during suppressive antiretroviral therapy.","volume":"222","author":"Falcinelli","year":"2020","journal-title":"J Infect Dis"},{"key":"2022101219182812300_CIT0020","doi-asserted-by":"crossref","first-page":"e139287","DOI":"10.1172\/jci.insight.139287","article-title":"Reduced HIV-1 latent reservoir outgrowth and distinct immune correlates among women in Rakai, Uganda.","volume":"5","author":"Prodger","year":"2020","journal-title":"JCI Insight"},{"key":"2022101219182812300_CIT0021","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.virol.2013.05.027","article-title":"17beta-estradiol inhibits HIV-1 by inducing a complex formation between beta-catenin and estrogen receptor alpha on the HIV promoter to suppress HIV transcription.","volume":"443","author":"Szotek","year":"2013","journal-title":"Virology"},{"key":"2022101219182812300_CIT0022","doi-asserted-by":"crossref","first-page":"E7795","DOI":"10.1073\/pnas.1803468115","article-title":"Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir.","volume":"115","author":"Das","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022101219182812300_CIT0023","volume-title":"I. Vorinostat","author":"Merck and Co.","year":"2006"},{"key":"2022101219182812300_CIT0024","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nprot.2008.108","article-title":"A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load.","volume":"3","author":"Malnati","year":"2008","journal-title":"Nat Protoc"},{"key":"2022101219182812300_CIT0025","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1128\/JCM.02060-14","article-title":"Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy.","volume":"52","author":"Cillo","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2022101219182812300_CIT0026","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0140-6736(19)32990-3","article-title":"Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.","volume":"395","author":"Fidler","year":"2020","journal-title":"Lancet"},{"key":"2022101219182812300_CIT0027","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12977-016-0268-7","article-title":"In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.","volume":"13","author":"Tsai","year":"2016","journal-title":"Retrovirology"},{"key":"2022101219182812300_CIT0028","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1198\/jcgs.2009.07130","article-title":"Fast implementation for normal mixed effects models with censored response.","volume":"18","author":"Vaida","year":"2009","journal-title":"J Comput Graph Stat"},{"key":"2022101219182812300_CIT0029","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S2055-6640(20)30047-9","article-title":"Statistical analysis of single-copy assays when some observations are zero.","volume":"5","author":"Bacchetti","year":"2019","journal-title":"J Virus Erad"},{"key":"2022101219182812300_CIT0030","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1089\/aid.2019.0284","article-title":"Participant perspectives in an HIV cure-related trial conducted exclusively in women in the United States: results from AIDS Clinical Trials Group 5366.","volume":"36","author":"Dube","year":"2020","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2022101219182812300_CIT0031","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1097\/QAD.0000000000000723","article-title":"Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy.","volume":"29","author":"Cuzin","year":"2015","journal-title":"AIDS"},{"key":"2022101219182812300_CIT0032","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jac\/dkt428","article-title":"Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy.","volume":"69","author":"Fourati","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2022101219182812300_CIT0033","doi-asserted-by":"crossref","first-page":"20290","DOI":"10.1073\/pnas.1312353110","article-title":"Cognition, mood, and physiological concentrations of sex hormones in the early and late postmenopause.","volume":"110","author":"Henderson","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022101219182812300_CIT0034","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/bjc.2011.156","article-title":"A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.","volume":"104","author":"Munster","year":"2011","journal-title":"Br J Cancer"},{"key":"2022101219182812300_CIT0035","author":"Celgene.","year":"2009"},{"key":"2022101219182812300_CIT0036","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/infdis\/jiu155","article-title":"HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.","volume":"210","author":"Archin","year":"2014","journal-title":"J Infect Dis"},{"key":"2022101219182812300_CIT0037","doi-asserted-by":"crossref","first-page":"e1004473","DOI":"10.1371\/journal.ppat.1004473","article-title":"Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.","volume":"10","author":"Elliott","year":"2014","journal-title":"PLoS Pathog"},{"key":"2022101219182812300_CIT0038","first-page":"jiab487","article-title":"Stable latent HIV infection and low-level viremia despite treatment with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent vorinostat.","author":"Gay","year":"2021","journal-title":"J Infect Dis"},{"key":"2022101219182812300_CIT0039","doi-asserted-by":"crossref","first-page":"100004","DOI":"10.1016\/j.jve.2020.100004","article-title":"A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection.","volume":"6","author":"Kroon","year":"2020","journal-title":"J Virus Erad"},{"key":"2022101219182812300_CIT0040","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","article-title":"Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial.","volume":"1","author":"Rasmussen","year":"2014","journal-title":"Lancet HIV"},{"key":"2022101219182812300_CIT0041","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/infdis\/jiaa777","article-title":"A phase I\/II randomized, placebo-controlled trial of romidepsin in persons with HIV-1 on suppressive antiretroviral therapy to assess safety and activation of HIV-1 expression (A5315).","volume":"224","author":"McMahon","year":"2020","journal-title":"J Infect Dis"},{"key":"2022101219182812300_CIT0042","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3389\/fimmu.2020.00823","article-title":"HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals: safety, immunogenicity and effect on the viral reservoir (study BCN02).","volume":"11","author":"Mothe","year":"2020","journal-title":"Front Immunol"},{"key":"2022101219182812300_CIT0043","doi-asserted-by":"crossref","first-page":"e1005142","DOI":"10.1371\/journal.ppat.1005142","article-title":"The depsipeptide romidepsin reverses HIV-1 latency in vivo.","volume":"11","author":"Sogaard","year":"2015","journal-title":"PLoS Pathog"},{"key":"2022101219182812300_CIT0044","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.bcp.2007.10.035","article-title":"Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling.","volume":"75","author":"Yi","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"2022101219182812300_CIT0045","doi-asserted-by":"crossref","first-page":"e0056021","DOI":"10.1128\/mBio.00560-21","article-title":"VIP-SPOT: an innovative assay to quantify the productive HIV-1 reservoir in the monitoring of cure strategies.","volume":"12","author":"Puertas","year":"2021","journal-title":"mBio"},{"key":"2022101219182812300_CIT0046","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1093\/infdis\/jiaa089","article-title":"Assessing the suitability of next-generation viral outgrowth assays to measure human immunodeficiency virus 1 latent reservoir size.","volume":"224","author":"Stone","year":"2021","journal-title":"J Infect Dis"},{"key":"2022101219182812300_CIT0047","doi-asserted-by":"crossref","first-page":"e92901","DOI":"10.1172\/jci.insight.92901","article-title":"HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.","volume":"2","author":"Wu","year":"2017","journal-title":"JCI Insight"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac136\/43370726\/ciac136.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/8\/1389\/46468749\/ciac136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/8\/1389\/46468749\/ciac136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T19:20:01Z","timestamp":1665602401000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/8\/1389\/6530348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,2,17]]},"published-print":{"date-parts":[[2022,10,12]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac136","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,15]]},"published":{"date-parts":[[2022,2,17]]}}}